tbuckley/cabot-search huggingface dataset:
In healthy older adults, aspirin did not affect disability-free survival or CVD but increased death and bleeding
Authors: Calvin Hirsch
Journal: Annals of Internal Medicine (2019)

ACP Journal Club15 January 2019In healthy older adults, aspirin did not affect disability-free survival or CVD but increased death and bleedingCalvin Hirsch, MDCalvin Hirsch, MDUC Davis Medical Center, Sacramento, California, USA (C.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2019-170-2-003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMcNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379:1499-1508. https://pubmed.ncbi.nlm.nih.gov/30221596Clinical Impact RatingsGIM/FP/GP: Geriatrics: Neurology: Public Health: References1 Rothwell PM, Cook NR, Gaziano JM, et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet. 2018;392:387-99. [PMID: 30017552] Google Scholar2 Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490-9. [PMID: 28622955] Google Scholar Author, Article, and Disclosure InformationAffiliations: UC Davis Medical Center, Sacramento, California, USA (C.H.)This article was published at Annals.org on 1 January 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 January 2019Volume 170, Issue 2Page: JC3KeywordsAspirinCardiovascular diseasesConfidence intervalsDementiaDisabilitiesElderlyHazard ratioHemorrhageMortalityPrevention, policy, and public health ePublished: 15 January 2019 Issue Published: 15 January 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
AB0910 Long-term golimumab retention rate in patients with psoriatic arthritis. is concomitant dmard important?
Authors: B. Serrano-Benavente, C.M. González-Fernández, L. Valor, I. Janta, R.D. González-Benítez, C. Sáenz Tenorio, J.C. Nieto-González, J.G. Ovalles-Bonilla, J. Martínez-Barrio, M. Correyero Plaza, L. García-Montoya, F.J. López-Longo, I. Monteagudo Saez
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The efficacy of Golimumab treatment in psoriatic arthritis (PsA) patients has been widely documented. <h3>Objectives</h3> The aim of this study was to analyse the long-term retention rate of golimumab and to identify independent predictors of drug retention in patients with PsA including concomitant synthetic disease-modifying antirheumatic drugs (sDMARD) <h3>Methods</h3> Prospective monocentric cohort of PsA patients treated with golimumab according to clinical practice. Study was approved by local Ethics Committee. Demographic and clinical variables were analysed with Cox proportional hazard regression model. <h3>Results</h3> 48 patients were included, 20/48 (41.7%) oligoarticular, 19/48 (39.6%) polyarticular and 9/48 (18.7%) with peripheral and axial PsA. The baseline characteristics of the patients are shown in table 1. Follow-up time was 89.25 patients-year. Mean survival time was 40.3 months (95% CI: 32.0–48.5). Age, mean evolution time and previous biological use were significant in the univariate analysis. Concomitant sDMARD had no influence on golimumab retention rate (HR: 1.3; 95% CI: 0.5–3.2; p: 0.6). Figure 1. When golimumab was used as first or second biologic treatment, it had a better retention rate than when it was used as third or fourth, but did not reach statistical significance (HR: 2.3; IC 95%: 0.8–6.2; p=0.1). 18/48 patients (37.5%) withdrew golimumab treatment. 13/18 (72.2%) due to lack of efficacy, 1/18 (0.6%) due to adverse events and 4/18 (22.2%) due to other reasons. <h3>Conclusions</h3> Real-world Golimumab retention rate in patients with PsA was good and did not depend on concomitant treatment with sDMARD. When used as first or second biologic, Golimumab retention rate tended to be better. <h3>Disclosure of Interest</h3> None declared
THU0402 Do we have good instruments to predict major cardiovascular events in systemic sclerosis patients?
Authors: C. Radu, L. Groseanu, T. Gudu, A. Balanescu, D. Predeteanu, V. Bojinca, D. Opris-Belinski, A. Borangiu, I. Saulescu, S. Daia-Iliescu, C. Constantinescu, D. Mazilu, F. Berghea, M.M. Negru, V. Vlad, M. Abobului, R. Ionescu
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> While macrovascular disease and higher cardiovascular (CV) risk are well documented in other systemic rheumatic diseases, the risk for major cardiovascular events for patients with systemic sclerosis (SSc) is yet to be established. <h3>Objectives</h3> The aim of the study was to determine the ability of different cardiovascular risk indices to predict major cardiovascular events (MACE) in systemic sclerosis. <h3>Methods</h3> The study included 144 patients followed in EUSTAR centre 096, but only patients with a follow-up for more then 10 years were selected for statistical analyses. Cardiovascular risk was estimated using QRiskII, <i>systemic</i> coronary <i>risk</i> evaluation (<i>SCORE</i>) and ACC/AHA risk indices. MACE were defined as: myocardial infarctions, strokes, peripheral vascular disease and cardiovascular related death. Data were compared by non-parametric tests. <h3>Results</h3> 32 patients, 31 females, 12 diffuse SSc subsets were included. The control group included 30 age and sex matched patients without autoimmune diseases. Mean age of the group was 52 years±SD 9.7, mean disease duration was 8 years±SD 9. The prevalence of traditional risk factors was: 13% smokers, significant family history 38%, obesity 16%, dyslipidemia 32%, older age 13%, hypertension 16%. There were no significant differences from the control group. Major cardiovascular events were: 13% myocardial infarction, 9% peripheral vascular disease, 9% CV related deaths. Concerning CV risk indices of the 32 SSc patients, 4 (13%) were classified as having high CV risk according to QRiskII/SCORE/ ACC risk.. In SSc patients, we could not identify any correlation between the above mentioned risk indices and MACE, including death of cardiovascular causes, except for a slight correlation between the SCORE and cardiovascular related death (p=0.04). <h3>Conclusions</h3> In our study, the main prediction indices were not correlated with the 10 year risk for CV events in SSc patients suggesting that we need better risk prediction tools. Both traditional risk factors and endothelial dysfunction have been proposed to participate at the onset and progression of vascular disease in SSc. Special attention should be paid to correct the traditional risk factors in combination with specific treatment for SSc. <h3>References</h3> [1] Psarras A, Soulaidopoulos S, Garyfallos A, Kitas G, Dimitroulas T A critical view on cardiovascular risk in systemic sclerosis. Rheumatol Int2017;37(1):85–95. [2] Groseanu L, Bojinca V, Gudu T, Saulescu I, Predeteanu D, Balanescu A, et al. Low vitamin D status in systemic sclerosis and the impact on disease phenotype Eur J Rheumatol2016;3(2):50–55. <h3>Disclosure of Interest</h3> None declared
SAT0503 Assessment of prostanoids (ILOPROST, ALPROSTADIL) efficacy in treatment of ulcers in patients with systemic sclerosis
Authors: M. Starovoytova, O. Desinova, O. Koneva, O. Ovsyannikova, L. Garzanova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The prostanoids are currently regarded as the most effective agents in treatment of ischaemic lesions in patients with rheumatic diseases. However, the efficacy of Alprostadil is underexplored, especially in comparison with Iloprost. <h3>Objectives</h3> To evaluate the efficacy of Alprostadil (Vazaprostan<sup>®</sup>) and Iloprost (Ilomedin®) in treatment of digital ulcers in SSc pts using modern assessment tools (questionnaires and designated forms) of digital ulcers. <h3>Methods</h3> This 1 year study included 42 patients with systemic scleroderma (SSc) aged &gt;18 y, having digital ulcers. Standard evaluation procedures and questionnaire to assess therapy, as well as scales and questionnaires for assessment of digital ulcers were used at baseline and after 12 months. The therapeutic regimens were as follows: Alprostadil at 20 mg/kg i/v drip rate infusion during 10 days, 1 course in 6 mo (totally 2 courses). Iloprost at 20 mg/kg i/v via infusion pump during 5 days each 3 months (totally 2 courses). The following questionnaires/forms to evaluate the therapy of digital ulcers were used: 1/VAS for pain assessment, 2/SSc-HAQ, 3/Cochin hand function scale, 4/the total hand pain score, 5/global patient's assessment of ulcers, 6/global physician's assessment of ulcers, 7/patient's evaluation of changes in ulcers, 8/physician's evaluation of changes in ulcers 9/number of digital ulcers. The patients were evaluated after the drug infusion and 1 year later. Clinical and demographic characteristics of patients treated with vasoactive drugs are presented in table 1. <h3>Results</h3> <h3>Results</h3> The results obtained show improvement of ischaemic lesions in both groups. The comparison of results speaks in favour of Vasoprostan vs Ilomedin in terms of significant pain reduction, table 2. <h3>Conclusions</h3> It should be noted that certain degree of positive dynamics in healing of ulcers was established by practically all assessment tools. VAS looks like the most sensitive tool in evaluation of pain. Of importance is the fact, that despite marked ischaemic lesions and digital ulcers, the Cochin score reflecting hand functional capacity did not exceed average values at baseline and did not change significantly post-treatment. <h3>Disclosure of Interest</h3> None declared
SAT0097 Risk of preventable hospitalisation before and after diagnosis among rheumatoid arthritis patients compared to controls
Authors: C.-F. Kuo, P.B. Burns, J.-S. Chen, L. Wang, K.C. Chung
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) generally requires intensive medical intervention, which along with the progression of the disease itself, may lead to the occurrence of comorbidities and hospitalisation that can be prevented with a quality primary care. We assessed the risk of preventable hospitalizations in RA patients, for whom preventable hospitalizations have not been well studied. We compare the incidence rate of preventable hospitalizations in newly-diagnosed RA patients and non-RA patients using data from the Taiwan National Health Insurance (NHI) Database. <h3>Objectives</h3> To investigate the risk of preventable hospitalisation before and after diagnosis between RA and non RA patients. <h3>Methods</h3> 11 852 incident RA patients and 59 260 age-, sex-, and index year-matched controls were identified from the Taiwan National Health Insurance Database. Index date was defined as the initial diagnosis date for RA patients and this date was assigned to their matched controls. The incidence and incidence rate ratios (IRRs) of preventable hospitalisation between RA patients and controls were estimated using conditional Poisson regression adjusted for age, sex, Elixhauser Comorbidity Index, number of outpatient visits and hospitalizations 1 year prior to index date, residence urbanisation, income levels, occupation and the number of physicians practicing near the patients' residence. <h3>Results</h3> The overall incidence of preventable hospitalisation in RA patients and controls was 1.71 vs 0.95 events per 1000 person-months, corresponding to adjusted incidence rate ratio (IRR) of 1.43 (95% CI, 1.35–1.51). The crude IRR for preventable hospitalisation was 1.84 (1.61–2.11) one year prior to RA diagnosis. Adjusted IRRs (95% CI) for preventable hospitalisation categories were 1.43 (1.22–1.67) for chronic obstructive pulmonary disease, 1.28 (1.02–1.62) for asthma, 1.76 (1.62–1.91) for bacterial pneumonia, 1.47 (1.35–1.61) for urinary tract infection. <h3>Conclusions</h3> This population-based study indicates that RA is independently associated with a higher risk of preventable hospitalisation, and the risk was already greater prior to formal diagnosis of RA. These results signal gaps in the care and management of RA patients in this population. <h3>Reference</h3> [1] Billings J, Anderson GM, Newman LS. Recent findings on preventable hospitalizations. Health Aff (Millwood)1996;15(3):239–249. <h3>Disclosure of Interest</h3> None declared
THU0563 Ultrasound changes in joints induced by intra-articular corticosteroid injection in juvenile idiopathic arthritis
Authors: B. Sozeri, L.G. Bolac, M. Kariminikoo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Ultrasonography (US) studies carried out on joints of juvenile idiopathic arthritis (JIA) patients in clinical remission demonstrate the presence of subclinical synovitis. The significance of subclinical synovitis and the positive power Doppler (PD) signal on US in JIA. <h3>Objectives</h3> The objectives of this study were to assess whether the changes detected by US induced by intra-articular corticosteroid injection in JIA patients. <h3>Methods</h3> We evaluated 49 joints (47 knees, 1 tibiotalar and 1 elbow) of 32 patients who diagnosed JIA. We used grey-scale US by high frequency transducer (7.5–10) MHz at study entry and after a therapeutic intervention. Each joint was scored for grey-scale (GS) and power Doppler (PD) abnormalities according to a 4-point semiquantitative scale. Pre- and post-treatment US scores were compared and the sensitivity to change of GSUS and PDUS was estimated. US assessment was performed separately, immediately after the clinical evaluation, by an experienced paediatric rheumatologist (BS) with certificated by EULAR. Medical records were reviewed for JIA subtype and state of disease. Clinical examination, including routine joint examination was carried. Clinical response was assessed using the ACR paediatric (pedi ACR) response criteria <h3>Results</h3> Five patients had polyarthritis, 5 had enthesitis-related arthritis, 22 had oligoarthritis. Nine patients (28%) underwent intra-articular corticosteroid injection (IACI) only, 23 (71,9%) were given IACI and systemic medications. The medication used were methotrexate (22 patients), Sulfasalazine (2 patients), and methotrexate and biologic (5 patient). Synovial hyperplasia, joint effusion, PD signal and tenosynovitis in at least one joint were detected in 77.4%, 100%, 33.3% and 15% of patients, respectively. Both GSUS and PDUS scores improved significantly (p&lt;0.0001) from baseline to follow-up. At the follow-up visit, 18/49 (36.7%) joints complete resolution among these patients 2 had minimal synovial hyperplasia. Although, 31/49 (63.3%) joints residual US abnormalities were judged in remission on clinical grounds. <h3>Conclusions</h3> US is a sensitive tool to assess therapeutic response in patients with JIA. Subclinical disease on US is common in joints with clinically-defined remission.. Further studies are needed to establish the impact of US on therapeutic decision-making in JIA. <h3>Disclosure of Interest</h3> None declared
A Functional Variant in Ubiquitin Conjugating Enzyme E2 L3 Contributes to Hepatitis B Virus Infection and Maintains Covalently Closed Circular DNA Stability by Inducing Degradation of Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3A
Authors: Li Zhou, Ji‐Hua Ren, Sheng‐Tao Cheng, Hong‐Mei Xu, Wei‐Xian Chen, Da‐Peng Chen, Vincent Kam Wai Wong, Betty Yuen Kwan Law, Yi Liu, Xue‐Fei Cai, Hua Tang, Hai‐Bo Yu, Jie‐Li Hu, Yuan Hu, Hong‐Zhong Zhou, Fang Ren, Lin He, Zhong‐Wen Hu, Hui Jiang, Hong‐Yan Xu, Ai‐Long Huang, Juan Chen
Journal: Hepatology (2019)

Hepatitis B virus (HBV) infection is a common infectious disease, in which nuclear covalently closed circular DNA (cccDNA) plays a key role in viral persistence, viral reactivation after treatment withdrawal, and drug resistance. A recent genome-wide association study has identified that the ubiquitin conjugating enzyme E2 L3 (UBE2L3) gene is associated with increased susceptibility to chronic HBV (CHB) infection in adults. However, the association between UBE2L3 and children with CHB and the underlying mechanism remain unclear. In this study, we performed two-stage case-control studies including adults and independent children in the Chinese Han population. The rs59391722 allele in the promoter of the UBE2L3 gene was significantly associated with HBV infection in both adults and children, and it increased the promoter activity of UBE2L3. Serum UBE2L3 protein levels were positively correlated with HBV viral load and hepatitis B e antigen (HBeAg) levels in children with CHB. In an HBV infection cell model, UBE2L3 knockdown significantly reduced total HBV RNAs, 3.5-kb RNA, as well as cccDNA in HBV-infected HepG2-Na+ /taurocholate cotransporting polypeptide cells and human primary hepatocytes. A mechanistic study found that UBE2L3 maintained cccDNA stability by inducing proteasome-dependent degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A, which is responsible for the degradation of HBV cccDNA. Moreover, interferon-α (IFN-α) treatment markedly decreased UBE2L3 expression, while UBE2L3 silencing reinforced the antiviral activity of IFN-α on HBV RNAs, cccDNA, and DNA. rs59391722 in UBE2L3 was correlated with HBV DNA suppression and HBeAg loss in response to IFN-α treatment of children with CHB. Conclusion: These findings highlight a host gene, UBE2L3, contributing to the susceptibility to persistent HBV infection; UBE2L3 may be involved in IFN-mediated viral suppression and serve as a potential target in the prevention and treatment of HBV infection.
Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Authors: Laura Rosinol Dachs, Benjamin Hebraud, Albert Oriol, Anne-Laurène Colin, Rafael Rios, Cyrille Hulin, Maria Jesús Blanchard, Denis Caillot, Anna Sureda, Miguel T Hernández, Bertrand Arnulf, Maria-Victoria Mateos, Margaret Macro, Jesús F San-Miguel, Karim Belhadj, Juan Jose Lahuerta, Guang Chen, M. Brigid Garelik, Joan Bladé, Philippe Moreau, Michel Attal
Journal: Blood (2018)
New Acute Myeloid Leukemia Therapy
Authors: Rebecca Voelker
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia
Authors: Francesca Arruga, Valeria Bracciamà, Alison Yeomans, Annalisa D'Avola, Marta Coscia, Giovanni Francesco D'Arena, Gianluca Gaidano, John N. Allan, Richard R. Furman, Graham Packham, Silvia Deaglio, Francesco Forconi
Journal: Blood (2018)
Reply to Biswas: Acute and Chronic Effects of Cigarette Smoking on sRAGE
Authors: Simon D. Pouwels, Frank Klont, Marcel Kwiatkowski, Valerie R. Wiersma, Alen Faiz, Maarten van den Berge, Péter Horvatovich, Rainer Bischoff, Nick H. T. ten Hacken
Journal: American Journal of Respiratory and Critical Care Medicine (2018)
AB1213 Ultrasonographic evaluation of the hip joints in patients with axial spondyloarthritis and psoriatic arthritis: associated with clinical and laboratory markers, imaging and functional outcomes
Authors: R. Osipyants, M. Bogdanova, M. Bilinskaya, D. Koshurnikov, A. Baev, T. Tamgina
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The hip joints are frequently involved in spondyloarthritis (SpA). Should ultrasonography (US) be additionally used for clinical assessment of disease in patients (pts) with SpA. <h3>Objectives</h3> to detect by US synovitis of the hip joints and to analyse the correlation between US finding and magnetic resonance imaging (MRI) and/or X-ray sacroiliitis, clinical and laboratory markers and functional status in pts with axial SpA (axSpA) and psoriatic arthritis (PsA). <h3>Methods</h3> 13 pts (7M/6F) with definite axSpA (7 with ankylosing spondylitis (AS) and 6 with non-radiographic nrSpA;ASAS) and 7 pts (4M/3F) with PsA (CASPAR) of similar age [median (IQR), 44<sup>35–55</sup> vs 42<sup>34–56</sup> years] and disease duration [7 (1–10) vs 9<sup>7–10</sup> years] were enrolled. US examination (Mindray DC-N6, C5–2 MHz probe) included bilateral of the hip joints according to the EULAR US Scanning App (www.eular.org; http://ultrasound.eular.org). MRI of sacroiliac joints (SIJ) was performed on Signa HDxT GE, 1.5 T. The bone marrow oedema on MRI (STIR) considered as active MRI sacroiliitis (MRI-SI).<sup>1</sup> X-ray of SIJs (modified New York criteria), functional status (BASFI), disease activity indices (ASDAS-CRP, DAPSA), laboratory tests (CRP, ESR, HLA-B27) were assessed. <h3>Results</h3> History of hip involvement was present in 7/20 (35%) pts who had ≥1 tender hip joint. 9/20 pts (45%) had US – synovitis of the hip joints. All pts were divided into two groups: g1(n=9) – US synovitis «+» (at least one hip joint), g2(n=11) – US -synovitis «-». Pts from g1 had higher CRP and BASFI compared to g2 (table 1). Elevated CRP ≥25 mg/L and ESR ≥30 mm/h, as well as MRI- and X-ray -SI were detected more often in g1pts than g2. But other parameters did not differ between the groups (table 1). US – synovitis of the hip joints was positively correlated with CRP (r=0.489, p&lt;0.05), MRI-SI (r=0.688,p&lt;0.05), X-ray-SI (r=0.634, p&lt;0.05) and BASFI (r=0.541, p&lt;0.05). <h3>Conclusions</h3> US – synovitis of the hip joints was associated with CRP, MRI- and X-ray- SI and severe functional disability in SpA pts. US evaluation of the hip joints may be used for identifying SpA pts with high risk of the disease progression at an early stage. <h3>Reference</h3> [1] Mandl P. et al. Ann Rheum Dis2015;0:1–13. <h3>Disclosure of Interest</h3> None declared